The National Institutes of Health (NIH) is inviting small businesses to apply for the NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) grant, aimed at supporting exploratory clinical trials for investigational therapies related to neurological disorders. This funding opportunity encourages the development of innovative trial designs and emphasizes the importance of commercial viability, particularly for projects that can secure independent third-party funding. Eligible applicants can request up to $1 million annually for Phase I studies and $1.5 million for Phase II studies, with project durations of up to two years for Phase I and three years for Phase II. The application deadline is September 5, 2024, and interested parties can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further information.